NCT05866432View on ClinicalTrials.gov

Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 1, 2023

Primary Completion Date

May 23, 2026

Study Completion Date

May 23, 2026

Conditions
Breast Cancer Stage IV
Interventions
DRUG

Datopotamab deruxtecan

Will be given until PD or withdraw

Trial Locations (1)

1090

RECRUITING

AKH Universitaetsklinikum Vienna, Department f. Internal medicine I, oncology, Vienna

Sponsors

Collaborators (1)

Daiichi Sankyo
All Listed Sponsors
collaborator

Daiichi Sankyo

INDUSTRY

lead

Medical University of Vienna

OTHER

NCT05866432 - Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases | Biotech Hunter | Biotech Hunter